ClinicalTrials.gg
CompletedNCT01255358IEDAT-01Updated Oct 10, 2024Results posted

Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Teleangiectasia Patients

A Phase 2 interventional study of Dexamethasone in Nervous System Disorder and Genetic Syndrome, sponsored by Quince Therapeutics S.p.A.. Completed at 2 sites in Italy. Open to participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2024-10-10.

Sponsored by Quince Therapeutics S.p.A. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
3 Years and older
Sex
All
01

Study summary

The study has the aim to evaluate the improvement in CNS symptoms measured by International Co-operative Ataxia Rating Scale (ICARS) in patients with ataxia teleangectasia (AT), during a period of treatment with ERY-DEX (dexamethasone sodium phosphate ex vivo encapsulated into human autologous erythrocytes).

Read the detailed description

This is a multi-centre, single arm, open label, 6 months, phase II study to evaluate the effect of ERY-DEX in improving Central Nervous System (CNS) symptoms in patients with Ataxia Teleangectasia (AT). The study consists of a screening period (max duration of 30 days) and a treatment period (duration 6 months).

02

Conditions studied

  • Nervous System Disorder
  • Genetic Syndrome

Keywords

  • Ataxia Teleangiectasia
  • AT
  • ERY-DEX
  • Dexamethasone
  • Dexamethasone sodium phosphate
03

In context

Nervous System Diseases

759 studies on the registry are indexed under Nervous System Diseases; 218 are open to participants now.

This study's enrollment of 22 is below the median of 55 across 496 interventional studies indexed under Nervous System Diseases.

Browse Nervous System Diseases studies →

Lead sponsor

Quince Therapeutics S.p.A. is the lead sponsor of 10 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • neurological signs of AT
  • patients in autonomous gait or helped by a support
  • proven molecular diagnosis of AT
  • Males and females aged > 3 years
  • Body weight >15 kg
  • Plasma levels of Lymphocytes CD4+/mm3 > 500 (for patients aged 3-6 years) or > 200 (older than 6 years)
  • written IC to participate.

Exclusion criteria

Exclusion Criteria:

  • Current or previous neoplastic disease
  • History of severe impairment of the immunological system
  • Chronic conditions representing a to the use of drugs
  • Non compliance with the study request
  • Any previous steroid assumption within 30 days before starting ERY-DEX
  • Have any other significant disease that in the Investigator's opinion would exclude the patient from the trial
  • Females of who were pregnant, breast-feeding or were not using adequate methods
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    ERY-DEX

    Patients treated with monthly treatment of ERY-DEX (dexamethasone sodium phosphate encapsulated in autologous erythrocytes)

    Drug: Dexamethasone

Interventions

  • Dexamethasone sodium phosphate (2 vials, 250 mg/10 ml each) to be administered via encapsulation into autologous erythrocytes (ERY-DEX system). Final amount administered to the patient: about 10-15 mg of dexamethasone sodium phosphate, encapsulated into autologous blood (2 vials of 250 mg each of dexamethasone sodium phosphate will be used in the ex vivo process together with 50 ml of blood previously taken from the same patient). The treatment has to be repeated at intervals of 30 days (±10 days)

    Also known as: Dexamethasone sodium phosphate, Dex 21P

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Neurological Symptoms Assessed by Using International Cooperative Ataxia Rating Scale (ICARS) Score - ITT Population

    ICARS ia a 100-point semiquantitative scale, which goes from 0 to 100, offering a compartimentalised quantification of 4 subscores: Posture and Gait Disturbances (maximum score = 34), Kinetic Functions (maximum score = 52), Speech Disorders (maximum score = 8), and Oculomotor Disorders (maximum score = 6) for a possible total score of 100 points. The minimum score is 0 (normal), while the maximum score is 100 and corresponds to the worst status of the patient. This means that for each subscale, higher scores indicate higher levels of impairment.

    Time frame: At visits 2 (day 30), 4 (day 90) and 7 (final visit, day 180)

  2. Mean Change From Baseline in Neurological Symptoms Assessed by Using International Cooperative Ataxia Rating Scale (ICARS) Score - PP Population

    ICARS ia a 100-point semiquantitative scale, which goes from 0 to 100, offering a compartimentalised quantification of 4 subscores: Posture and Gait Disturbances (maximum score = 34), Kinetic Functions (maximum score = 52), Speech Disorders (maximum score = 8), and Oculomotor Disorders (maximum score = 6) for a possible total score of 100 points. The minimum score is 0 (normal), while the maximum score is 100 and corresponds to the worst status of the patient. This means that for each subscale, higher scores indicate higher levels of impairment.

    Time frame: At visits 2 (day 30), 4 (day 90) and 7 (final visit, day 180)

Secondary outcomes

  1. Change From V4 to V7 in Investigator Global Assessment (IGA) - ITT Population

    An evaluation of the global health status of the patients by the IGA was performed. IGA consisted of an evaluation of neurological signs and symptoms as neuromotor disorders, posture and deambulation, disturbances of the oro-pharyngeal apparatus, presence of peripheral neuropathy, neurodevelopmental disturbances, intellectual level, and behavior disturbances based only on a subjective judgment of the Investigator on a single scale: a 5-point qualitative scale as: * very much improved (1), * slightly improved (2), * no change (3), * slightly worsened (4), * very much worsened (5) was used to assess changes from V4 to V7. The higher the score, the worse the outcome.

    Time frame: At visit 7 (final visit, day 180)

  2. Change From V4 to V7 in Investigator Global Assessment (IGA) - PP Population

    An evaluation of the global health status of the patients by the IGA was performed. IGA consisted of an evaluation of neurological signs and symptoms as neuromotor disorders, posture and deambulation, disturbances of the oro-pharyngeal apparatus, presence of peripheral neuropathy, neurodevelopmental disturbances, intellectual level, and behavior disturbances based only on a subjective judgment of the Investigator on a single scale: a 5-point qualitative scale as: * very much improved (1), * slightly improved (2), * no change (3), * slightly worsened (4), * very much worsened (5) was used to assess changes from V4 to V7. The higher the score, the worse the outcome.

    Time frame: At visit 7 (final visit, day 180)

  3. Mean Change From V4 to V7 in Ocular Motility - ITT Population

    An evaluation of ocular motility measured by an ad hoc form was performed at V4 and V7. At V4 and V7, ocular motility was assessed through a 5-point qualitative scale: very much improved (1), slightly improved (2), no change (3), slightly worsened (4), very much worsened (5).

    Time frame: At visit 7 (final visit, day 180)

  4. Mean Change From V4 to V7 in Ocular Motility - PP Population

    An evaluation of ocular motility measured by an ad hoc form was performed at V4 and V7. At V4 and V7, ocular motility was assessed through a 5-point qualitative scale: very much improved (1), slightly improved (2), no change (3), slightly worsened (4), very much worsened (5).

    Time frame: At visit 7 (final visit, day 180)

  5. Change From Baseline for Vineland Adaptive Behaviour Scale (VABS) Total Score - ITT Population

    VABS aggregate scale is used. VABS is divided into 4 adaptive domains and 11 subdomains: 1. Communication: Receptive, Expressive, Written; 2. Daily Living Skills: Personal, Domestic, Community; 3. Socialisation: Interpersonal Relationships, Play \& Leisure Time, Coping Skills; 4. Motor Skills: Gross, Fine. For each \*question\* in each of the 11 subdomains, score ranges from 0 to 4 (the higher the value the better the outcome): * 0 = the subject never performs the behaviour without help or reminders; * 1 = rarely performs (as above); * 2 = sometimes performs (as above); * 3 = often performs (as above); * 4 = almost always performs (as above); The total subdomain score is the sum of each \*question\* scores and the total domain score is the sum of each subdomains' scores. Domains min-max interval scores: 0-74 Communication, 0-74 Daily Living Skills, 0-62 Socialization, 0-111 Motor Skills, Sum-of-domains score 0-321(the higher the score, the better the outcome)

    Time frame: At visits 4 (90 days) and 7 (180 days, final visit)

  6. Change From Baseline for Vineland Adaptive Behaviour Scale (VABS) Total Score - PP Population

    VABS aggregate scale is used. VABS is divided into 4 adaptive domains and 11 subdomains: 1. Communication: Receptive, Expressive, Written; 2. Daily Living Skills: Personal, Domestic, Community; 3. Socialisation: Interpersonal Relationships, Play \& Leisure Time, Coping Skills; 4. Motor Skills: Gross, Fine. For each \*question\* in each of the 11 subdomains, score ranges from 0 to 4 (the higher the value the better the outcome): * 0 = the subject never performs the behaviour without help or reminders; * 1 = rarely performs (as above); * 2 = sometimes performs (as above); * 3 = often performs (as above); * 4 = almost always performs (as above); The total subdomain score is the sum of each \*question\* scores and the total domain score is the sum of each subdomains' scores. Domains min-max interval scores: 0-74 Communication, 0-74 Daily Living Skills, 0-62 Socialization, 0-111 Motor Skills, Sum-of-domains score 0-321(the higher the score, the better the outcome)

    Time frame: At visits 4 (90 days) and 7 (180 days, final visit)

  7. Count of Participants on ERY-DEX Showing Treatment Emergent Adverse Events (TEAEs) Including Serious Adverse Events (SAEs)

    The effect of ERY-DEX on treatment emergent adverse events was expressed as the number of patients showing at least one TEAE or 1 serious AE

    Time frame: Throughout the study, until the end of 6 months of treatment (day 180)

07

Results

Posted Oct 10, 2024

Participant flow

Study was carried out in 2 Italian Hospitals. Recruitment started on February 2011 and LPLV was performed on August 2011.

Participant flow — Overall Study
MilestoneEryDex
Started22
Completed18
Not completed4
Withdrew: Adverse event2
Withdrew: Protocol violation2

Outcome measures

PrimaryMean Change From Baseline in Neurological Symptoms Assessed by Using International Cooperative Ataxia Rating Scale (ICARS) Score - ITT Population

ICARS ia a 100-point semiquantitative scale, which goes from 0 to 100, offering a compartimentalised quantification of 4 subscores: Posture and Gait Disturbances (maximum score = 34), Kinetic Functions (maximum score = 52), Speech Disorders (maximum score = 8), and Oculomotor Disorders (maximum score = 6) for a possible total score of 100 points. The minimum score is 0 (normal), while the maximum score is 100 and corresponds to the worst status of the patient. This means that for each subscale, higher scores indicate higher levels of impairment.

Time frame:
At visits 2 (day 30), 4 (day 90) and 7 (final visit, day 180)
Reported as:
Mean · units on a scale
Mean Change From Baseline in Neurological Symptoms Assessed by Using International Cooperative Ataxia Rating Scale (ICARS) Score - ITT Population
units on a scaleERY-DEX
V2-2.2 ± 5.6
V4-3.4 ± 7.3
V7-4.0 ± 7.5
Statistical analysis
  • ERY-DEX · Wilcoxon (Mann-Whitney) · p = 0.02 · Mean difference (final values): -4.0 · 95% CI -7.1 to -0.9
PrimaryMean Change From Baseline in Neurological Symptoms Assessed by Using International Cooperative Ataxia Rating Scale (ICARS) Score - PP Population

ICARS ia a 100-point semiquantitative scale, which goes from 0 to 100, offering a compartimentalised quantification of 4 subscores: Posture and Gait Disturbances (maximum score = 34), Kinetic Functions (maximum score = 52), Speech Disorders (maximum score = 8), and Oculomotor Disorders (maximum score = 6) for a possible total score of 100 points. The minimum score is 0 (normal), while the maximum score is 100 and corresponds to the worst status of the patient. This means that for each subscale, higher scores indicate higher levels of impairment.

Time frame:
At visits 2 (day 30), 4 (day 90) and 7 (final visit, day 180)
Reported as:
Mean · units on a scale
Mean Change From Baseline in Neurological Symptoms Assessed by Using International Cooperative Ataxia Rating Scale (ICARS) Score - PP Population
units on a scaleERY-DEX
V2-2.4 ± 4.9
V4-3.9 ± 7.1
V7-5.2 ± 7.0
Statistical analysis
  • ERY-DEX · Wilcoxon (Mann-Whitney) · p = 0.0031 · Mean difference (final values): -5.2 · 95% CI -8.4 to -2
SecondaryChange From V4 to V7 in Investigator Global Assessment (IGA) - ITT Population

An evaluation of the global health status of the patients by the IGA was performed. IGA consisted of an evaluation of neurological signs and symptoms as neuromotor disorders, posture and deambulation, disturbances of the oro-pharyngeal apparatus, presence of peripheral neuropathy, neurodevelopmental disturbances, intellectual level, and behavior disturbances based only on a subjective judgment of the Investigator on a single scale: a 5-point qualitative scale as: * very much improved (1), * slightly improved (2), * no change (3), * slightly worsened (4), * very much worsened (5) was used to assess changes from V4 to V7. The higher the score, the worse the outcome.

Time frame:
At visit 7 (final visit, day 180)
Reported as:
Mean · units on a scale
Change From V4 to V7 in Investigator Global Assessment (IGA) - ITT Population
units on a scaleERY-DEX
Change From V4 to V7 in Investigator Global Assessment (IGA) - ITT Population0.2 ± 0.6
SecondaryChange From V4 to V7 in Investigator Global Assessment (IGA) - PP Population

An evaluation of the global health status of the patients by the IGA was performed. IGA consisted of an evaluation of neurological signs and symptoms as neuromotor disorders, posture and deambulation, disturbances of the oro-pharyngeal apparatus, presence of peripheral neuropathy, neurodevelopmental disturbances, intellectual level, and behavior disturbances based only on a subjective judgment of the Investigator on a single scale: a 5-point qualitative scale as: * very much improved (1), * slightly improved (2), * no change (3), * slightly worsened (4), * very much worsened (5) was used to assess changes from V4 to V7. The higher the score, the worse the outcome.

Time frame:
At visit 7 (final visit, day 180)
Reported as:
Mean · units on a scale
Change From V4 to V7 in Investigator Global Assessment (IGA) - PP Population
units on a scaleERY-DEX
Change From V4 to V7 in Investigator Global Assessment (IGA) - PP Population0.2 ± 0.6
SecondaryMean Change From V4 to V7 in Ocular Motility - ITT Population

An evaluation of ocular motility measured by an ad hoc form was performed at V4 and V7. At V4 and V7, ocular motility was assessed through a 5-point qualitative scale: very much improved (1), slightly improved (2), no change (3), slightly worsened (4), very much worsened (5).

Time frame:
At visit 7 (final visit, day 180)
Reported as:
Mean · units on a scale
Mean Change From V4 to V7 in Ocular Motility - ITT Population
units on a scaleERY-DEX
Mean Change From V4 to V7 in Ocular Motility - ITT Population-0.3 ± 0.5
SecondaryMean Change From V4 to V7 in Ocular Motility - PP Population

An evaluation of ocular motility measured by an ad hoc form was performed at V4 and V7. At V4 and V7, ocular motility was assessed through a 5-point qualitative scale: very much improved (1), slightly improved (2), no change (3), slightly worsened (4), very much worsened (5).

Time frame:
At visit 7 (final visit, day 180)
Reported as:
Mean · units on a scale
Mean Change From V4 to V7 in Ocular Motility - PP Population
units on a scaleERY-DEX
Mean Change From V4 to V7 in Ocular Motility - PP Population-0.3 ± 0.5
SecondaryChange From Baseline for Vineland Adaptive Behaviour Scale (VABS) Total Score - ITT Population

VABS aggregate scale is used. VABS is divided into 4 adaptive domains and 11 subdomains: 1. Communication: Receptive, Expressive, Written; 2. Daily Living Skills: Personal, Domestic, Community; 3. Socialisation: Interpersonal Relationships, Play \& Leisure Time, Coping Skills; 4. Motor Skills: Gross, Fine. For each \*question\* in each of the 11 subdomains, score ranges from 0 to 4 (the higher the value the better the outcome): * 0 = the subject never performs the behaviour without help or reminders; * 1 = rarely performs (as above); * 2 = sometimes performs (as above); * 3 = often performs (as above); * 4 = almost always performs (as above); The total subdomain score is the sum of each \*question\* scores and the total domain score is the sum of each subdomains' scores. Domains min-max interval scores: 0-74 Communication, 0-74 Daily Living Skills, 0-62 Socialization, 0-111 Motor Skills, Sum-of-domains score 0-321(the higher the score, the better the outcome)

Time frame:
At visits 4 (90 days) and 7 (180 days, final visit)
Reported as:
Mean · units on a scale
Change From Baseline for Vineland Adaptive Behaviour Scale (VABS) Total Score - ITT Population
units on a scaleERY-DEX
V41.0 ± 0.9
V71.3 ± 1.3
Statistical analysis
  • ERY-DEX · Wilcoxon (Mann-Whitney) · p = <0.0001 · Median difference (final values): 1.3 · 95% CI 0.8 to 1.8
SecondaryChange From Baseline for Vineland Adaptive Behaviour Scale (VABS) Total Score - PP Population

VABS aggregate scale is used. VABS is divided into 4 adaptive domains and 11 subdomains: 1. Communication: Receptive, Expressive, Written; 2. Daily Living Skills: Personal, Domestic, Community; 3. Socialisation: Interpersonal Relationships, Play \& Leisure Time, Coping Skills; 4. Motor Skills: Gross, Fine. For each \*question\* in each of the 11 subdomains, score ranges from 0 to 4 (the higher the value the better the outcome): * 0 = the subject never performs the behaviour without help or reminders; * 1 = rarely performs (as above); * 2 = sometimes performs (as above); * 3 = often performs (as above); * 4 = almost always performs (as above); The total subdomain score is the sum of each \*question\* scores and the total domain score is the sum of each subdomains' scores. Domains min-max interval scores: 0-74 Communication, 0-74 Daily Living Skills, 0-62 Socialization, 0-111 Motor Skills, Sum-of-domains score 0-321(the higher the score, the better the outcome)

Time frame:
At visits 4 (90 days) and 7 (180 days, final visit)
Reported as:
Mean · units on a scale
Change From Baseline for Vineland Adaptive Behaviour Scale (VABS) Total Score - PP Population
units on a scaleERY-DEX
V41.1 ± 0.9
V71.5 ± 1.1
Statistical analysis
  • ERY-DEX · Wilcoxon (Mann-Whitney) · p = <0.0001 · Mean difference (final values): 1.5 · 95% CI 1 to 2
SecondaryCount of Participants on ERY-DEX Showing Treatment Emergent Adverse Events (TEAEs) Including Serious Adverse Events (SAEs)

The effect of ERY-DEX on treatment emergent adverse events was expressed as the number of patients showing at least one TEAE or 1 serious AE

Time frame:
Throughout the study, until the end of 6 months of treatment (day 180)
Reported as:
Count of participants · Participants
Count of Participants on ERY-DEX Showing Treatment Emergent Adverse Events (TEAEs) Including Serious Adverse Events (SAEs)
ParticipantsERY-DEX
Participants with at least 1 TEAE15
Participants with at least 1 serious AE2

Adverse events

Collected over The adverse events were monitored and collected during the 6 month study period. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ery-Dex0/22 (0%)2/22 (9.1%)15/22 (68.2%)
Most frequent serious events
Most frequent serious events
EventEry-Dex
BronchopneumoniaInfections and infestations1/22
BronchiectasisRespiratory, thoracic and mediastinal disorders1/22
Most frequent other events
Most frequent other events
EventEry-Dex
infections and infestationsInfections and infestations15/22
respiratory disordersRespiratory, thoracic and mediastinal disorders4/22
General disordersGeneral disorders3/22
immune disordersImmune system disorders2/22

Baseline characteristics

The study enrolled 22 patients, 11 male and 11 female with a mean age of 11.2. All the enrolled patients received a monthly treatment of EryDex for 6 consecutive months.

Age, Categorical
Age, Categorical(Participants)ERY-DEX
<=18 years21
Between 18 and 65 years1
>=65 years0
Age, Continuous
Age, Continuous(years)ERY-DEX
Mean11.2 ± 3.5
Sex: Female, Male
Sex: Female, Male(Participants)ERY-DEX
Female11
Male11
Region of Enrollment
Region of Enrollment(participants)ERY-DEX
Italy22
08

Study locations

2 sites
  • Spedali Civili
    Brescia, 25123, Italy
  • University La Sapienza
    Rome, 00185, Italy
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2011 to primary completion in Sep 2011, 7 months.

Results were first posted in Oct 2024, 13 years 1 month after primary completion.

Of 49 phase 2 interventional studies under Nervous System Diseases, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's 7 months is below that.

Nervous System Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2010
First posted
Dec 7, 2010
StartActual
Feb 2011
Primary completionActual
Sep 2011
CompletionActual
Dec 2011
Results first posted
Oct 10, 2024
Last update
Oct 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01255358
Lead sponsor
Quince Therapeutics S.p.A.
Responsible party
Sponsor
First posted
Dec 7, 2010
Start date
Feb 2011
Primary completion
Sep 2011
Completion
Dec 2011
Results posted
Oct 10, 2024
Last update
Oct 10, 2024

Study contacts

Luciana Chessa, MD
principal investigator · A.O. Sant'Andrea Rome Italy

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion